Biodexa Pharmaceuticals plc, in collaboration with Emtora Biosciences, has been awarded an additional $3.0 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This new funding increases the total CPRIT grant support for the eRapa Phase 3 program in familial adenomatous polyposis (FAP) to $20.0 million. The grant will facilitate the inclusion of more clinical sites, expedite patient recruitment, and potentially accelerate the availability of this treatment option for patients who currently have no alternatives other than surgical intervention. The Phase 3 study, a double-blind placebo-controlled trial, will involve 168 patients and is set to commence recruitment in the coming weeks across approximately 30 clinical sites in the US and Europe.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.